FAQ/Help |
Calendar |
Search |
Today's Posts |
08-16-2016, 10:48 AM | #1 | ||
|
|||
Member
|
|
||
Reply With Quote |
08-16-2016, 07:01 PM | #2 | ||
|
|||
Member
|
Quote:
|
||
Reply With Quote |
08-17-2016, 11:27 AM | #3 | ||
|
|||
Senior Member
|
The referenced research uses "functional magnetic resonance imaging to reveal areas where Parkinson's disease and related conditions cause progressive decline in brain activity".
The ability to "see" what is happening in the brain is enormously useful in understanding the pathogenesis of the disease. But, I am skeptical about its usefulness as a biomarker: it has high cost; it is hospital based, forcing the patient to go to travel; observations are likely to be infrequent; and most importantly the measure that comes from this imaging, perhaps size of the affected area, is a proxy for the real impact of the disease, which is reflected in the symptoms. In my opinion, a better way forward is to measure the symptoms of the disease. This can be done objectively, with high frequency (perhaps every second) and as the patient goes about his life. One way to do this is to use accelerometers to measure movements of the body. On the issue of the placebo effect. I understand that in Parkinson's the placebo effect is more than just the perception that a therapy improves the condition. Rather, it is a stronger effect: as measured externally and objectively, it does improve the condition, and not just the perception of it. Some would argue that a placebo is effective for a shorter period than a "true" therapy. In my opinion, a placebo is as much a true therapy as a drug. It needs to be engineered, measured and judged against more conventional therapies. Fortunately, it is not the case that we can only have an organic effect or a placebo effect, the best therapies will have both. John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
Reply With Quote |
08-17-2016, 12:56 PM | #4 | ||
|
|||
Member
|
Quote:
I vaguely recall reading about a neuro in the uk who is looking into paradoxical kinesia after watching one of his Px's shuffle across the road,slow and stooped only to take off like a bullet to avoid an ambulance racing to casualty. I believe he thought it was something to do with acetylcholine. On the subject of measuring/monitoring progression to provide effective treatment again I agree. If I'm struggling with my gait or losing confidence in my ability to perform daily tasks then I know, as does my neuro, who observes my level of ability and makes med. change suggestions. I fail to see what having a scan can bring to the party......unless it says ' everything looks normal ' which would upset the apple cart ! There are cases of Dat scan results which show a normal picture yet the subject presents in a classical Parkinsonian manner. User error or another indication that at least some PD subset types may be due to other additional neurotransmitter involvement ? Nigel |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Breakthrough MRI finding - potential new early PD biomarker | Parkinson's Disease | |||
Study could lead to Parkinson's treatment breakthrough February 6th, 2014 | Parkinson's Disease | |||
A new levodopa product could improve the treatment of advanced Parkinson's patients | Parkinson's Disease | |||
Parkinson's disease: Treatment breakthrough in mice opens new path | Parkinson's Disease |